Storia in 11 fonti

FDA greenlights Revolution Medicines' pancreatic cancer gamechanger

Following dynamite data that earned a standing ovation at the American Society of Clinical Oncology meeting in May, Revolution Medicines’ RAS inhibitor daraxonrasib has been

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo12 h fa

FDA greenlights Revolution Medicines' pancreatic cancer gamechanger

Following dynamite data that earned a standing ovation at the American Society of Clinical Oncology meeting in May, Revolution Medicines’ RAS inhibitor daraxonrasib has been

originale

Timeline cronologica

mercoledì 26 agosto 2026·healio.com
Rasonque nabs FDA approval for previously treated metastatic pancreatic adenocarcinoma
The FDA has approved a first-in-class targeted therapy for adults with metastatic pancreatic adenocarcinoma. Daraxonrasib (Rasonque, Revolution Medicines), an RAS inhibitor,…
mercoledì 26 agosto 2026·biopharmadive.com
Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly…

FDA greenlights Revolution Medicines' pancreatic cancer gamechanger

Confronto fonti

FDA greenlights Revolution Medicines' pancreatic cancer gamechanger

Timeline cronologica

Rasonque nabs FDA approval for previously treated metastatic pancreatic adenocarcinoma

Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA

FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy

FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer

Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA

Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug - Revolution Medicines (NA

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | CNN

FDA approves new pancreatic cancer drug expected to usher in new era of treatment

FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy

FDA greenlights Revolution Medicines' pancreatic cancer gamechanger

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | CNN

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | The Jerusalem Post

FDA approves ‘game-changing’ pancreatic cancer drug

FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer

Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug - Revolution Medicines (NA